Mark Varney, Ph.D.

Dr. Varney is the Chief Scientific Officer of PsychoGenics, a preclinical CRO with expertise in CNS and orphan disorders. He… Continue reading Mark Varney, Ph.D.

Harry Tracy, Ph.D.

Dr. Tracy is the founder and President of NI Research (NIR), the leading publisher of independent research on the neurotherapeutics industry. NIR’s bimonthly publication, NeuroPerspective, has provided comprehensive and frank overviews of the neurotherapeutics sector since 1995.

Reid Robison, M.D., MBA

Dr. Robison is the Chief Medical Officer of Novamind, a mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. He is a founding board member at Psychedelic Institute, a non-profit dedicated to compassionate access to psychedelic therapies.

Bruce H. Morimoto, Ph.D.

Dr. Morimoto is a drug development consultant currently helping several biotech companies move their programs through clinical development and drug registration. He is also VP of Drug Development for Cerecin, a biopharmaceutical company focused on brain therapeutics.

Judith Jaeger, Ph.D., MPA

Dr. Jaeger is President and Principal Scientist at CognitionMetrics which provides consultation to the pharmaceutical industry on the measurement of cognitive and behavioral change in clinical trials for both efficacy and safety. She is also a Professor of Psychiatry and Behavioral Sciences at Albert Einstein College of Medicine.

Mark S. Cohen, Ph.D.

Dr. Cohen is the Technical Director of the Staglin Center for Cognitive Neuroscience at the UCLA School of Medicine. He is also the Director of the UCLA/Semel Neuroimaging Training Program, and he holds appointments in the UCLA Departments of Psychiatry & Biobehavioral Sciences, Neurology, Radiology, Biomedical Physics, Psychology, and Bioengineering.